Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
CLINICAL TRANSPLANTATION, vol.32, no.8, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 32 Issue: 8
- Publication Date: 2018
- Doi Number: 10.1111/ctr.13345
- Journal Name: CLINICAL TRANSPLANTATION
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Istanbul University-Cerrahpasa Affiliated: No
Abstract
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.